Compare Iron Mountain Inc (IRM) vs Moderna, Inc. (MRNA) Price & Performance

Iron Mountain (IRM) trades at $124.55, up 2.46% on the day, with a bearish technical signal but strong recent earnings beats. Revenue growth is robust, reaching $6.90B in 2025, though net margins are thin at 5.54%. The stock shows high valuation multiples, including a P/E of 86.8, and carries significant debt, with total liabilities at $18.94B. Analyst consensus is bullish with a $141.50 price target, supported by institutional buying and positive Q2 2026 results highlighted by data center growth.

Outlook is cautiously optimistic due to earnings momentum and data center expansion, but high debt and declining paper storage pose risks. The stock offers potential upside to the consensus target, yet investors must weigh valuation concerns against operational strengths.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.